Two landmark transactions announced this week have reset expectations for cross-border deal activity in 2025. German life sciences group Merck KGaA has agreed to acquire U.S.-based Bio-Techne for $11.3 billion — its largest acquisition in over a decade — while ON Semiconductor has announced an all-stock acquisition of Synaptics valued at $7 billion, targeting the fast-expanding market for AI-enabled edge devices. Together, these deals represent more than $18 billion in disclosed transaction value and reflect a structural shift in how global corporations are deploying capital: with precision, urgency, and a clear mandate to acquire capabilities that organic growth cannot deliver fast enough.

Life Sciences and Physical AI: The New Frontiers of Strategic Consolidation

The Merck KGaA–Bio-Techne transaction is a textbook example of capability-driven mergers and acquisitions. Bio-Techne, a Minneapolis-based provider of proteins, antibodies, and analytical instruments for life science research, fills a critical gap in Merck’s Life Science division — one that has faced intensifying competition from Thermo Fisher Scientific and Danaher. For CFOs and M&A Directors evaluating comparable transactions, the deal illustrates a recurring theme: premium valuations are increasingly justified by proprietary platform assets and recurring revenue streams tied to research workflows, not merely top-line growth.

ON Semiconductor’s acquisition of Synaptics moves in a parallel but distinct direction. By absorbing Synaptics’ human interface and IoT silicon portfolio, ON Semi is positioning itself at the intersection of semiconductor manufacturing and physical AI — the deployment of machine learning in devices that interact with the physical world. This all-stock structure deserves attention from corporate finance teams: it signals confidence in combined equity upside while preserving cash for integration and R&D investment. For CTOs and board members, the deal raises a strategic question worth internalizing — in AI hardware, is your company acquiring the stack, or ceding it to competitors who are?

Parallel Deal Flow: Defense, Energy Infrastructure, and Consumer Health

Beyond the headline transactions, the broader deal landscape this week reveals several converging vectors that decision-makers should monitor closely.

  • Defense and drone technology: French aerospace group Safran has entered exclusive negotiations to acquire sea drone specialist Exail Technologies at €128.5 per share, reflecting accelerating European consolidation in dual-use defense technology. With EU member states increasing defense budgets under NATO commitments and the European Defence Fund expanding its remit, cross-border deals in this sector will face heightened scrutiny under foreign direct investment (FDI) screening mechanisms, including France’s own décret Montebourg framework.
  • Energy infrastructure: KKR‘s agreement to acquire EDF Power Solutions across the U.S. and Canada from EDF underscores sustained private equity appetite for regulated and contracted energy assets. For General Counsel, transactions of this type increasingly require navigation of CFIUS review in the United States alongside sector-specific regulatory approvals — a dual-track compliance burden that demands early engagement.
  • Consumer health: Haleon‘s bid for Thorne targets a $70 billion U.S. supplements market that has attracted significant venture capital and strategic interest since the pandemic. The deal reflects a broader pattern of consumer health spin-offs — Haleon itself was carved out of GSK in 2022 — now redeploying capital into bolt-on acquisitions to build category scale.

Implications for Cross-Border Deal Execution in 2025

For M&A Directors and advisory teams, the current environment presents both opportunity and complexity. Several practical implications warrant attention:

  • Due diligence scope is expanding. In AI-adjacent transactions, technical due diligence must now encompass model governance, data licensing rights, and semiconductor supply chain dependencies — areas where traditional financial due diligence frameworks are insufficient.
  • Regulatory timelines are lengthening. Cross-border deals touching defense, semiconductors, or critical infrastructure are subject to parallel review under the EU Foreign Subsidies Regulation (FSR), CFIUS, and national FDI regimes. Boards should budget 12–18 months for regulatory clearance in complex cases.
  • Post-merger integration remains the value inflection point. Merck KGaA’s track record with Sigma-Aldrich — acquired for $17 billion in 2015 and successfully integrated into its Life Science division — demonstrates that disciplined post-merger integration is the differentiator between transformative and dilutive acquisitions. Cultural alignment, technology stack harmonization, and talent retention must be addressed in the first 100 days.

Key takeaway: The $18B+ in deals announced this week is not an anomaly — it is an early indicator of a sustained M&A cycle driven by capability gaps in AI, life sciences, and defense. For boards and executive teams, the strategic question is not whether to pursue inorganic growth, but whether your organization has the deal architecture, regulatory readiness, and integration infrastructure to execute at this pace and scale.